Published in Nucleic Acid Ther on October 30, 2013
Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy. Nucleic Acid Ther (2014) 0.97
Development of therapeutic splice-switching oligonucleotides. Hum Gene Ther (2014) 0.88
Regulation of mammalian transcription and splicing by Nuclear RNAi. Nucleic Acids Res (2015) 0.83
Parallel synthesis of cell-penetrating peptide conjugates of PMO toward exon skipping enhancement in Duchenne muscular dystrophy. Nucleic Acid Ther (2014) 0.83
The delivery of therapeutic oligonucleotides. Nucleic Acids Res (2016) 0.82
Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy. Nucleic Acids Res (2014) 0.81
Modulation of Splicing by Single-Stranded Silencing RNAs. Nucleic Acid Ther (2015) 0.80
Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy. Nucleic Acid Ther (2017) 0.77
An amphipathic trans-acting phosphorothioate DNA element delivers uncharged PNA and PMO nucleic acid sequences in mammalian cells. Curr Protoc Nucleic Acid Chem (2016) 0.75
Poly(ester amine) Composed of Polyethylenimine and Pluronic Enhance Delivery of Antisense Oligonucleotides In Vitro and in Dystrophic mdx Mice. Mol Ther Nucleic Acids (2016) 0.75
Welcome to the splice age: antisense oligonucleotide-mediated exon skipping gains wider applicability. J Clin Invest (2016) 0.75
Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy. Mol Ther Nucleic Acids (2015) 0.75
An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes. RSC Adv (2017) 0.75
Synthesis of oligonucleotides on a soluble support. Beilstein J Org Chem (2017) 0.75
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science (2009) 10.30
PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature (1993) 8.83
Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med (2011) 5.91
Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A (1987) 5.17
Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet (2011) 4.81
Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol (2013) 4.57
Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev (1997) 4.25
Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med (2006) 3.74
RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov (2012) 3.70
Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science (2009) 3.62
Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A (2004) 3.34
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev (2010) 3.02
Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther (2008) 2.69
Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci U S A (2003) 2.65
Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature (2012) 2.63
Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med (2011) 2.56
Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol (2002) 2.38
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.32
Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med (2006) 2.18
A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet (2011) 2.13
Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci U S A (2008) 2.06
Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res (2008) 1.98
Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov (2011) 1.89
Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther (2009) 1.76
Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet (2008) 1.69
Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res (2001) 1.67
Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res (2010) 1.67
In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med (2009) 1.66
Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J Neurosci (2009) 1.64
Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem (2009) 1.61
Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res (2008) 1.52
Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther (2009) 1.52
Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res (2008) 1.49
Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther (2007) 1.48
Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta (2010) 1.47
Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev (2007) 1.47
Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol Ther (2006) 1.42
Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol Ther Nucleic Acids (2012) 1.41
Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2'-O-methyl/LNA oligoribonucleotides. Biochemistry (2001) 1.33
Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A (2012) 1.32
Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther (2011) 1.32
Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther (2004) 1.31
Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci (2009) 1.31
Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res (2007) 1.28
Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing. Nat Chem Biol (2012) 1.22
Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr Res (2006) 1.22
Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry (2002) 1.19
Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2'-O-methoxyethyl-modified oligonucleotide. J Immunol (2006) 1.19
A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Hum Gene Ther (2013) 1.17
An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models. Mol Ther (2008) 1.15
Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino. Am J Pathol (2012) 1.10
Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier. Mol Ther Nucleic Acids (2013) 1.10
Dystrophin restoration in skeletal, heart and skin arrector pili smooth muscle of mdx mice by ZM2 NP-AON complexes. Gene Ther (2009) 1.08
Bifunctional RNAs targeting the intronic splicing silencer N1 increase SMN levels and reduce disease severity in an animal model of spinal muscular atrophy. Mol Ther (2011) 1.07
Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor. Nucleic Acids Res (2010) 1.05
TricycloDNA-modified oligo-2'-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues--a comparative study of oligonucleotide length, design and chemistry. Nucleic Acids Res (2012) 1.03
Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Mol Ther (2010) 0.98
Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice. J Biomed Biotechnol (2012) 0.97
Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther (2012) 0.95
Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing. Nucleic Acids Res (2004) 0.94
Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing. Mol Pharmacol (2000) 0.93
Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients. J Invest Dermatol (2006) 0.93
An octaguanidine-morpholino oligo conjugate improves muscle function of mdx mice. Muscle Nerve (2011) 0.93
Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy. Nucleic Acid Ther (2013) 0.92
Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP). Mol Ther Nucleic Acids (2013) 0.91
Target mRNA inhibition by oligonucleotide drugs in man. Nucleic Acids Res (2012) 0.89
Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the murine interleukin-5 receptor-alpha chain. Biochemistry (2001) 0.89
Functionalized PEG-PEI copolymers complexed to exon-skipping oligonucleotides improve dystrophin expression in mdx mice. Hum Gene Ther (2008) 0.88
Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of duchenne muscular dystrophy. Int J Toxicol (2011) 0.87
Effective exon skipping and dystrophin restoration by 2'-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice. PLoS One (2013) 0.86
Peptide nucleic acids conjugated to short basic peptides show improved pharmacokinetics and antisense activity in adipose tissue. J Med Chem (2010) 0.86
Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo. Mol Ther (2013) 0.86
Design and analysis of effects of triplet repeat oligonucleotides in cell models for myotonic dystrophy. Mol Ther Nucleic Acids (2013) 0.85
Polyethylenimine-modified pluronics (PCMs) improve morpholino oligomer delivery in cell culture and dystrophic mdx mice. Mol Ther (2012) 0.84
Long-term Exon Skipping Studies With 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models. Mol Ther Nucleic Acids (2012) 0.83
Ultrasound-enhanced delivery of morpholino with Bubble liposomes ameliorates the myotonia of myotonic dystrophy model mice. Sci Rep (2013) 0.83
Tricyclo-DNA containing oligonucleotides as steric block inhibitors of human immunodeficiency virus type 1 tat-dependent trans-activation and HIV-1 infectivity. Oligonucleotides (2007) 0.82
Development of a general methodology for labelling peptide-morpholino oligonucleotide conjugates using alkyne-azide click chemistry. Chem Commun (Camb) (2013) 0.81
Parallel synthesis and splicing redirection activity of cell-penetrating peptide conjugate libraries of a PNA cargo. Org Biomol Chem (2013) 0.80
Development of novel bioanalytical methods to determine the effective concentrations of phosphorodiamidate morpholino oligomers in tissues and cells. Biores Open Access (2013) 0.80
Chimeric RNA and 2'-O, 4'-C-ethylene-bridged nucleic acids have stronger activity than phosphorothioate oligodeoxynucleotides in induction of exon 19 skipping in dystrophin mRNA. Oligonucleotides (2004) 0.78
Design of 2'-O-Me RNA/ENA chimera oligonucleotides to induce exon skipping in dystrophin pre-mRNA. Nucleic Acids Symp Ser (Oxf) (2004) 0.77
Preparation and properties of 2',5'-linked oligonucleotide analogues containing 3'-O,4'-C-methyleneribonucleosides. Bioorg Med Chem Lett (1999) 0.76
Synthesis of 2'-O-[2-(N-methylcarbamoyl)ethyl]ribonucleosides using oxa-Michael reaction and chemical and biological properties of oligonucleotide derivatives incorporating these modified ribonucleosides. J Org Chem (2011) 0.75
miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA (2007) 1.90
Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy. Mol Ther Nucleic Acids (2012) 1.53
Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res (2008) 1.52
Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev (2007) 1.47
Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells. Nucleic Acids Res (2005) 1.44
Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol Ther Nucleic Acids (2012) 1.41
Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res (2010) 1.41
Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates. J Control Release (2005) 1.38
RNA-targeted splice-correction therapy for neuromuscular disease. Brain (2010) 1.36
Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther (2011) 1.32
Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res (2007) 1.28
Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides. Nucleic Acids Res (2005) 1.27
RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. Blood Cells Mol Dis (2006) 1.22
Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. Hum Mol Genet (2010) 1.19
MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol Biosyst (2006) 1.10
MicroRNA fate upon targeting with anti-miRNA oligonucleotides as revealed by an improved Northern-blot-based method for miRNA detection. RNA (2011) 1.02
Synthesis of peptide-oligonucleotide conjugates with single and multiple peptides attached to 2'-aldehydes through thiazolidine, oxime, and hydrazine linkages. Bioconjug Chem (2002) 1.00
Chemical structure requirements and cellular targeting of microRNA-122 by peptide nucleic acids anti-miRs. Nucleic Acids Res (2011) 1.00
Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Mol Ther (2010) 0.98
PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res (2011) 0.97
Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA. Mol Ther Nucleic Acids (2012) 0.95
Disulfide conjugation of peptides to oligonucleotides and their analogs. Curr Protoc Nucleic Acid Chem (2006) 0.93
In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. J Gene Med (2010) 0.93
A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2'-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), alpha-L-LNA, or 2'-thio-LNA residues. Oligonucleotides (2003) 0.92
A peptide-based dendrimer that enhances the splice-redirecting activity of PNA conjugates in cells. Bioconjug Chem (2009) 0.92
Cell-penetrating peptides do not cross mitochondrial membranes even when conjugated to a lipophilic cation: evidence against direct passage through phospholipid bilayers. Biochem J (2004) 0.91
Loop-loop interaction of HIV-1 TAR RNA with N3'-->P5' deoxyphosphoramidate aptamers inhibits in vitro Tat-mediated transcription. Proc Natl Acad Sci U S A (2002) 0.91
Pyrenemethyl ara-uridine-2'-carbamate: a strong interstrand excimer in the major groove of a DNA duplex. Chembiochem (2003) 0.90
2'-O-methyl-RNA hairpins generate loop-loop complexes and selectively inhibit HIV-1 Tat-mediated transcription. Biochemistry (2002) 0.90
Lipoplex and peptide-based strategies for the delivery of steric-block oligonucleotides. Int J Pharm (2007) 0.89
Synthesis and biological activity of phosphonoacetate- and thiophosphonoacetate-modified 2'-O-methyl oligoribonucleotides. Org Biomol Chem (2011) 0.89
Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy. Mol Ther Nucleic Acids (2012) 0.89
Targeting the HIV-1 RNA leader sequence with synthetic oligonucleotides and siRNA: chemistry and cell delivery. Biochim Biophys Acta (2005) 0.88
Overview of alternative oligonucleotide chemistries for exon skipping. Methods Mol Biol (2012) 0.88
Exploiting cell surface thiols to enhance cellular uptake. Trends Biotechnol (2012) 0.88
Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents. Artif DNA PNA XNA (2012) 0.87
Synthesis and splice-redirecting activity of branched, arginine-rich peptide dendrimer conjugates of peptide nucleic acid oligonucleotides. Bioconjug Chem (2010) 0.87
Use of carbonyl group addition--elimination reactions for synthesis of nucleic acid conjugates. Bioconjug Chem (2005) 0.86
Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells. Nucleic Acids Res (2013) 0.86
Antiviral activity of steric-block oligonucleotides targeting the HIV-1 trans-activation response and packaging signal stem-loop RNAs. Nucleosides Nucleotides Nucleic Acids (2005) 0.85
Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide. RNA (2009) 0.85
Chemical modifications to improve the cellular uptake of oligonucleotides. Curr Top Med Chem (2007) 0.84
Oligonucleotide analogs as antiviral agents. Curr Opin Mol Ther (2006) 0.84
A bi-functional siRNA construct induces RNA interference and also primes PCR amplification for its own quantification. Nucleic Acids Res (2005) 0.84
First synthesis of an aziridinyl fused pyrrolo[1,2-a]benzimidazole and toxicity evaluation towards normal and breast cancer cell lines. Org Biomol Chem (2011) 0.84
Peptide-based delivery of steric-block PNA oligonucleotides. Methods Mol Biol (2009) 0.83
Hexitol nucleic acid-containing aptamers are efficient ligands of HIV-1 TAR RNA. Biochemistry (2005) 0.83
Synthesis of oligonucleotide 2'-conjugates via amide bond formation in solution. Bioorg Med Chem Lett (2004) 0.83
Parallel synthesis of cell-penetrating peptide conjugates of PMO toward exon skipping enhancement in Duchenne muscular dystrophy. Nucleic Acid Ther (2014) 0.83
Total stepwise solid-phase synthesis of oligonucleotide-(3'-->N)-peptide conjugates. Org Lett (2002) 0.82
Systematic screening of LNA/2'-O-methyl chimeric derivatives of a TAR RNA aptamer. FEBS Lett (2007) 0.82
Tricyclo-DNA containing oligonucleotides as steric block inhibitors of human immunodeficiency virus type 1 tat-dependent trans-activation and HIV-1 infectivity. Oligonucleotides (2007) 0.82
Development of a general methodology for labelling peptide-morpholino oligonucleotide conjugates using alkyne-azide click chemistry. Chem Commun (Camb) (2013) 0.81
Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. J Clin Invest (2014) 0.80
Parallel synthesis and splicing redirection activity of cell-penetrating peptide conjugate libraries of a PNA cargo. Org Biomol Chem (2013) 0.80
PNA-peptide conjugates as intracellular gene control agents. Nucleic Acids Symp Ser (Oxf) (2008) 0.80
Peptide-based in vivo delivery agents for oligonucleotides and siRNA. Nucleic Acid Ther (2012) 0.79
Steric inhibition of human immunodeficiency virus type-1 Tat-dependent trans-activation in vitro and in cells by oligonucleotides containing 2'-O-methyl G-clamp ribonucleoside analogues. Nucleic Acids Res (2003) 0.79
LNA and alpha-L-LNA: towards therapeutic applications. Nucleosides Nucleotides Nucleic Acids (2003) 0.78
Inhibition of HIV-1 replication by oligonucleotide analogues directed to the packaging signal and trans-activating response region. Antivir Chem Chemother (2006) 0.78
Anti-HIV activity of steric block oligonucleotides. Ann N Y Acad Sci (2006) 0.77
Chemical methods for peptide-oligonucleotide conjugate synthesis. Methods Mol Biol (2005) 0.77
Splice redirection as a convenient assay to monitor CPP-ON efficiency and mechanism. Methods Mol Biol (2011) 0.76
Oligonucleotides containing 2'-O-[2-(2,3-dihydroxypropyl)amino-2-oxoethyl]uridine as suitable precursors of 2'-aldehyde oligonucleotides for chemoselective ligation. Bioorg Med Chem (2005) 0.76
Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides. Nucleic Acid Ther (2015) 0.75
Comparative studies of tricyclo-DNA- and LNA-containing oligonucleotides as inhibitors of HIV-1 gene expression. Nucleosides Nucleotides Nucleic Acids (2007) 0.75
Nucleic acids: new life, new materials. Org Biomol Chem (2013) 0.75
2'-Functionalized nucleic acids as structural tools in molecular biology. IUBMB Life (2004) 0.75
1,2-Diol and hydrazide phosphoramidites for solid-phase synthesis and chemoselective ligation of 2'-modified oligonucleotides. Nucleosides Nucleotides Nucleic Acids (2003) 0.75
Corrigendum: Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics. Sci Rep (2016) 0.75
The synthesis of 2'-O-methyl G-clamp containing oligonucleotides and their inhibition of the HIV-1 Tat-TAR interaction. Nucleosides Nucleotides Nucleic Acids (2003) 0.75
The influence of the aziridinyl substituent of benzimidazoles and benzimidazolequinones on toxicity towards normal and Fanconi anaemia cells. Eur J Med Chem (2010) 0.75
(R)-2,4-Dihydroxybutyramide seco-pseudonucleosides: new versatile homochiral synthons for synthesis of modified oligonucleotides. Org Lett (2002) 0.75
Incorporation of side-chain groups of basic amino acids into oligonucleotides via the 2'-position of uridine. Nucleic Acids Symp Ser (Oxf) (2005) 0.75
Total stepwise solid-phase peptide-oligonucleotide conjugate synthesis on macroporous polystyrene. Nucleosides Nucleotides Nucleic Acids (2003) 0.75
Preparation of 2'-hydrazino oligonucleotides and their reaction with aldehydes and 1,3-diketones. Nucleosides Nucleotides Nucleic Acids (2007) 0.75
Uridine 2'-carbamates: facile tools for oligonucleotide 2'-functionalization. Curr Protoc Nucleic Acid Chem (2004) 0.75
Steric block high affinity oligonucleotide analogues: a new tool for mapping RNA-protein binding sites. Nucleosides Nucleotides Nucleic Acids (2008) 0.75
In Vitro Assays to Assess Exon Skipping in Duchenne Muscular Dystrophy. Methods Mol Biol (2015) 0.75
2'-Hydrazine oligonucleotides: synthesis and efficient conjugation with aldehydes. Nucleic Acids Symp Ser (Oxf) (2005) 0.75